The price of cancer drugs is too high, an increasingly significant issue in U.S. health care expenditures. In this op-ed for the Washington Post, Hagop Kantarjian, scholar in health policy, explains how to reduce the price of cancer drugs.
Kirstin R.W. Matthews , Ana S. Iltis , Daniel S. Wagner
Feb 26 2021 | Center for Health and Biosciences
Feb 26 2021 | Center for Energy Studies